⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22182043 | 0.74 | — | — | |
| SCHEMBL14403784 | 0.74 | — | — | |
| SCHEMBL11320623 | 0.74 | — | — | |
| Catechol SCHEMBL28985421 | 0.74 | ALDH1A1 (0.77) | — | |
| Catechol SCHEMBL132726 | 0.74 | ALDH1A1 (0.77) | — | |
| SCHEMBL24553843 | 0.70 | CA2 (0.43) | — | |
| SCHEMBL24040373 | 0.69 | CA12 (0.64) | — | |
| Catechol SCHEMBL30944695 | 0.69 | ALDH1A1 (1.00) | — | |
| Catechol SCHEMBL367675 | 0.69 | ALDH1A1 (1.00) | — | |
| Catechol SCHEMBL29352716 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023205219-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS | BERG LLC (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2021142247-A1 | SMARCA2-VHL DEGRADERS | AMGEN INC. (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2019195201-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |